Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No Intervention: Observational Cohort.
- Who it may be relevant to
- Registry conditions: Idiopathic Parkinsonism. Basic parameters: from 20 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Taiwan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Validation of a Mobile Health Application for Fall Risk Assessment in Parkinson's Disease: A Comparative Study Before and After Dopaminergic Medication Adjustment
Overview
This is a single-center, prospective observational study aiming to validate the Kinetikos Health App for fall risk assessment in PD patients undergoing dopaminergic medication adjustments.
Detailed description
Falls are common and disabling in PD. Dopaminergic medication effects on fall risk remain inconclusive. This study validates the Kinetikos Health App for objective fall risk assessment before and after medication adjustment.
Interventions
- Other No Intervention: Observational Cohort
No intervention.
Primary outcome measures
- Change in fall-risk index (Kinetikos Health App Sit-to-Stand) [Time frame: From baseline to 3 months]
Secondary outcome measures (3)
- UPDRS [Time frame: From baseline to 3 months]
- Fall events [Time frame: From baseline to 3 months]
- LEDD [Time frame: From baseline to 3 months]
Eligibility criteria
Inclusion criteria
- Age ≥20;
- PD diagnosis (MDS criteria);
- On levodopa monotherapy with motor fluctuations;
- Planned to start opicapone or safinamide;
- Consent provided.
Exclusion criteria
- Atypical/secondary parkinsonism;
- Moderate-severe dementia;
- DBS/MRgFUS/neurosurgery within 6 months;
- Severe comorbidities limiting test
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Taiwan · 1 center
- Shuang Ho Hospital, Taipei Medical University — New Taipei City
Identifiers
NCT: NCT07257393 · N202511067